Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

AGM Statement

23 Oct 2008 14:25

RNS Number : 5547G
Marchpole Holdings PLC
23 October 2008
 



23 October 2008

Marchpole Holdings plc

("Marchpole" or "the Company")

Annual General Meeting Statement

At Marchpole Holdings Annual General Meeting held this morning the Chairman of Marchpole Holdings plc, Christopher Phillips, gave the following statement and update on current trading.

"At the time of the announcement on 5 August 2008 of our results for the 53 weeks ended 5 April 2008 we reported that the year to date had proved to be challenging, with very difficult trading conditions leading to a substantial loss for the full year. However, it has also been a year of significant change and some progress for the Group, as we continue to evolve into a diversified international luxury brand management business with a globally recognised portfolio of fashion brands.

Most recently we announced a successful fund raising of £2.5 million with Atlas Design, which provides the Company with a more secure foundation from which to pursue growth opportunities as they arise. In addition we have also appointed Atlas Chairman Peter Wahlberg and Atlas CEO Allan Ladow to the Board of Marchpole as non-executive directors, and we look forward to benefiting from the additional experience that they bring to the Company.

Significantly during the current financial period we have entered into a joint venture and licensing agreement with the DKNY menswear label, under the terms of which Marchpole will source, design, produce and distribute a full range of DKNY menswear apparel throughout the world, excluding the Indian and Japanese markets. The agreement is for an initial period of seven years, with the option to extend the licence for a further seven years.

Trading conditions in the current financial year continue to be extremely difficult as a result of the deterioration in consumer markets, following the ongoing global financial crisis. 

The Board is taking all appropriate measures to deal with the current challenging economic environment and is maintaining a regular dialogue with the Company's bankers, in common with most other businesses exposed to the retail sector. In the current environment the directors continue to review all options and will provide an update on the trading performance with the interim statement in early December."

For further information please contact:

For further information, please contact :

Bell Pottinger Corporate & Financial 020 7861 3232

David Rydell / Emma Kent

Marchpole Holdings plc 020 7908 7777

Chris Phillips, Chairman

Michael MorrisExecutive Deputy Chairman 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGMUOUORWRRRUAA
Date   Source Headline
10th Sep 20191:00 pmRNSNotice of Results
6th Sep 20197:00 amRNSBlock listing Interim Review
4th Sep 20191:00 pmRNSMereo announces phase 2b data at ASBMR Meeting
16th Aug 20191:51 pmRNSDirector/PDMR Shareholding
15th Aug 20194:59 pmRNSPDMR Shareholding
12th Aug 20194:41 pmRNSSecond Price Monitoring Extn
12th Aug 20194:35 pmRNSPrice Monitoring Extension
9th Aug 20194:35 pmRNSPrice Monitoring Extension
31st Jul 201912:51 pmRNSDirector Declaration
25th Jul 20194:56 pmRNSPDMR Shareholding
24th Jul 201910:08 amRNSDirector/PDMR Shareholding
19th Jul 20191:21 pmRNSDirector/PDMR Shareholding
16th Jul 20191:00 pmRNSAppointment of Richard Francis
15th Jul 20191:00 pmRNSSuccessful Type B Meeting with U.S. FDA
8th Jul 20193:54 pmRNSHolding(s) in Company
3rd Jul 20194:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
27th Jun 20193:33 pmRNSHolding(s) in Company
26th Jun 20194:36 pmRNSHolding(s) in Company
21st Jun 20191:00 pmRNSConversion of loan note and issue of equity
20th Jun 20197:00 amRNSResult of AGM
13th Jun 20191:00 pmRNSUpdate on Etigilimab (TIGIT) Partnership
30th May 20197:00 amRNSPositive early 6 month data
23rd May 20194:11 pmRNSDirector/PDMR Shareholding
22nd May 20199:45 amRNSPDMR Shareholding
21st May 20193:08 pmRNSDirector/PDMR Shareholding
20th May 20197:00 amRNSNotice of AGM
8th May 20191:53 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSIssue of Warrants
7th May 20197:00 amRNSRe-release: Intention to Purchase Shares
3rd May 20195:00 pmRNSIntention to Purchase Shares by Trustee of EBT
3rd May 20192:02 pmRNSDirector/PDMR Shareholding
1st May 20193:47 pmRNSDirector/PDMR Shareholding
30th Apr 20193:15 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSPublication of Annual Report and Accounts
29th Apr 20197:00 amRNSPrelims Results for year ended December 31 2018
26th Apr 20193:01 pmRNSDirector/PDMR Shareholding
25th Apr 20193:36 pmRNSHolding(s) in Company
25th Apr 20193:29 pmRNSHolding(s) in Company
24th Apr 20192:30 pmRNSAdmission to Trading
23rd Apr 20192:25 pmRNSCompletion of Merger
18th Apr 20197:00 amRNSMerger Update
15th Apr 20197:00 amRNSSuccessful end of Phase 2 Meeting with FDA
21st Mar 20197:00 amRNSPublication of Form F-4
15th Mar 201911:45 amRNSUpdate on Proposed Combination of Mereo & OncoMed
13th Mar 201911:00 amRNSMereo CEO appointed NED of Elanco Animal Health
6th Mar 20197:00 amRNSBlock Listing Interim Review
5th Mar 20191:32 pmRNSMereo to present at Cowen and Company Conference
22nd Feb 20191:50 pmRNSUpdate on Proposed Transaction with OncoMed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.